Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK

Abstract The imidazolium compound YM155, first discovered as a potent inhibitor of Survivin, effectively kills many carcinomas in preclinical models. However, the upstream signaling mechanism triggered by YM155 remains unclear. Here we studied early signaling responses in vitro in prostate and renal...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: David Danielpour, Zhaofeng Gao, Patrick M. Zmina, Eswar Shankar, Benjamin C. Shultes, Raul Jobava, Scott M. Welford, Maria Hatzoglou
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
R
Q
Acceso en línea:https://doaj.org/article/413a98d689b543009470d4c60ab64d4b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!